aTyr Pharma Presents Preclinical Research Showing NRP2 Antibody Effects in Triple-Negative Breast Cancer at the 2020 AACR Virtual Annual Meeting II
June 22, 2020 08:00 ET
|
aTyr Pharma, Inc.
Poster details data from aTyr’s preclinical, domain specific Neuropilin-2 (NRP2) antibody program showing antibodies may increase sensitivity to chemotherapy in triple-negative breast cancer. SAN...
aTyr Pharma Highlights New Literature Implicating Neuropilin Pathway In SARS-CoV-2 Infection
June 17, 2020 17:00 ET
|
aTyr Pharma, Inc.
Discovery that Neuropilin b1 domain acts as a binding site for SARS-CoV-2 Spike protein and aids viral entry. Lead therapeutic candidate, ATYR1923, modulates Neuropilin pathway to dampen inflammatory...
aTyr Pharma Announces Dosing of First Patient in Phase 2 Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications
June 15, 2020 07:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, June 15, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...
aTyr Pharma Announces First Quarter 2020 Results and Provides Corporate Update on ATYR1923 Clinical Trials in Pulmonary Sarcoidosis and COVID-19
May 12, 2020 16:05 ET
|
aTyr Pharma, Inc.
SAN DIEGO, May 12, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...
aTyr Pharma Announces Research Collaboration with Boston Children’s Hospital
October 22, 2019 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Oct. 22, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...
aTyr Pharma to Participate in September Conferences
September 18, 2019 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Sept. 18, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel...
aTyr Pharma to Present at the H.C. Wainwright 21st Annual Global Investment Conference
September 04, 2019 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Sept. 04, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel...
aTyr Pharma Announces Second Quarter 2019 Results and Provides Corporate Update
August 14, 2019 08:00 ET
|
aTyr Pharma, Inc.
aTyr to report interim safety results from Phase 1b/2a proof-of-concept trial of ATYR1923 in pulmonary sarcoidosis patients in Q4 2019 Company to host conference call and webcast today, August...
aTyr Pharma to Announce Second Quarter 2019 Results on August 14th
August 07, 2019 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Aug. 07, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...
Leading Immunobiology Researcher Dr. David Briscoe Joins aTyr Pharma as Scientific Advisor
August 06, 2019 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Aug. 06, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines, today announced the...